Role of targeting ferroptosis as a component of combination therapy in combating drug resistance in colorectal cancer

World J Clin Oncol. 2024 Mar 24;15(3):375-377. doi: 10.5306/wjco.v15.i3.375.ABSTRACTColorectal cancer (CRC) is a form of cancer that is often resistant to chemotherapy, targeted therapy, radiotherapy, and immunotherapy due to its genomic instability and inflammatory tumor microenvironment. Ferroptosis, a type of non-apoptotic cell death, is characterized by the accumulation of iron and the oxidation of lipids. Studies have revealed that the levels of reactive oxygen species and glutathione in CRC cells are significantly lower than those in healthy colon cells. Erastin has emerged as a promising candidate for CRC treatment by diminishing stemness and chemoresistance. Moreover, the gut, responsible for regulating iron absorption and release, could influence CRC susceptibility through iron metabolism modulation. Investigation into ferroptosis offers new insights into CRC pathogenesis and clinical management, potentially revolutionizing treatment approaches for therapy-resistant cancers.PMID:38576594 | PMC:PMC10989259 | DOI:10.5306/wjco.v15.i3.375
Source: Clinical Colorectal Cancer - Category: Cancer & Oncology Authors: Source Type: research